Last Updated : December 2, 2020
Details
FilesGeneric Name:
Atezolizumab & Bevacizumab
Project Status:
Complete
Therapeutic Area:
Hepatocellular Carcinoma (HCC)
Manufacturer:
Hoffmann-La Roche Limited
Brand Name:
Tecentriq & Avastin
Project Line:
Reimbursement Review
Project Number:
PC0217-000
NOC Status at Filing:
Pre NOC
Performance Metric:
Achieved
Strength:
1200 mg/20 mL and 840 mg/14 mL
Tumour Type:
Gastrointestinal
Indications:
Hepatocellular Carcinoma (HCC)
Funding Request:
TECENTRIQ (atezolizumab), in combination with AVASTIN (bevacizumab), for the first-line treatment of adult patients with unresectable or metastatic hepatocellular carcinoma (HCC) who require systemic therapy. Maintenance TECENTRIQ should continue until loss of clinical benefit or unacceptable toxicity. Maintenance AVASTIN should continue until loss of clinical benefit or unacceptable toxicity.
Pre Noc Submission:
Yes
Sponsor:
Hoffmann-La Roche Limited
Submission Date:
Submission Deemed Complete:
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommendation Type:
Reimburse with clinical criteria and/or conditions
pERC Meeting:
Final Recommendation Issued:
Files
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Last Updated : December 2, 2020